CorrellCU, CitromeL, HaddadPM, et al.The use of long-acting injectable antipsychotics in Schizophrenia: Evaluating the evidence. J Clin Psychiatry, 2016; 77(Suppl 3):1–24; doi: 10.4088/JCP.15032su1
2.
GarzonJF, ElmaadawiAZ, AaronsonST, et al.A multisite, 6-Month, open-label study of maintenance transcranial magnetic stimulation for adolescents with treatment-resistant depression. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0067
3.
HarlinM, YildirimM, SuchP, et al.A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar I disorder. CNS Drugs, 2023; 37(4):337–350; doi: 10.1007/s40263-023-00996-8
4.
MeyerA, TrumanK, TotLaniJ, et al.Systematic review of long-acting injectable antipsychotic medications approved from 2008 to october 2024 and agents in phase 3. Int J Psychiatry Med, 2024:912174241310091; doi: 10.1177/00912174241310091
5.
PacchiarottiI, TiihonenJ, KotzalidisGD, et al.Long-Acting Injectable Antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. Eur Neuropsychopharmacol, 2019; 29(4):457–470; doi: 10.1016/j.euroneuro.2019.02.003
6.
ParikhP, SoodK, BansalLR, et al.Long-Acting injectable antipsychotics in adolescents with bipolar disorder. J Child Adolesc Psychopharmacol, 2025; doi: 10.1089/cap.2024.0088
7.
ScharkoAM, MireskiSJ. A 16-year-old male with autism spectrum disorder, psychosis, and refusal to accept any oral medication: A case report and use of long-acting injectable aripiprazole lauroxil. J Child Adolesc Psychopharmacol, 2024b; doi: 10.1089/cap.2024.0052
8.
ScharkoAM, MireskiSJ, CasimirK, et al.Use of long-acting injectable antipsychotic medication in youth at winnebago mental health institute: A clinical pathway. J Child Adolesc Psychopharmacol, 2024c; doi: 10.1089/cap.2024.0106
9.
ScharkoAM, SierackiR, MireskiSJ. Long-Acting injectable antipsychotic medication use in youth: A systematic review of the literature along with medwatch safety data and prescriber attitudes. J Child Adolesc Psychopharmacol, 2024a; doi: 10.1089/cap.2024.0106
10.
SunC, TemelieA, GouldingH, et al.Comparison of psychiatric readmission rates for child and adolescent patients on long-acting injectable antipsychotics versus oral antipsychotics: A mirror study. J Child Adolesc Psychopharmacol, 2024b; doi: 10.1089/cap.2024.0072
11.
SunC, TemelieA, GouldingH, et al.Long-Acting injectable antipsychotic initiation in child and adolescent patients with psychiatric disorders. J Child Adolesc Psychopharmacol, 2024a; doi: 10.1089/cap.2024.0024
